Latest Breaking News On - Limitations associated - Page 6 : comparemela.com

  Gross profit decreased $1.7 million to $79.7 million. Gross margin decreased to 75.5% compared to 77.7% in the prior year period. Net loss was $(5.8) million, or $(0.30) per share, compared to net income of $25.7 million, or $1.32 per share in the prior year period. Adjusted net income was $3.4 million, or $0.17 per share, compared to adjusted net income of $1.7 million, or $0.09 per share in the prior year period. EBITDA was $1.8 million, compared to $12.4 million in the prior year period. Adjusted EBITDA was $14.0 million, or 13.3% of net sales, compared to $11.4 million, or 10.9% of net sales, in the prior year period. Liquidity As of March 31, 2021, cash, cash equivalents, and restricted cash totaled $95.1 million compared to $96.8 million as of December 31, 2020. As of March 31, 2021, the Company had no borrowings under its five year $300 million secured revolving credit facility. Cash flow from operations decreased $10.0 million to $2.4 million, while free cash flow dec

United statesJon serbousekDrug administrationUniversity of modenaOrthofix incExchange commissionOrthofix medical incSecurities exchangeEuropean union medical device regulationOrthofix presidentChief executive officer jonMonths ended marchExclusive licensePulsed electromagnetic fieldLow intensity pulsed ultrasoundCapacitive coupling